NCT01818232

Study to Determine the Absorption, Metabolism, and Excretion of [14C]LX4211 in Healthy Male Subjects

A Phase 1, Open-label, Nonrandomized, Single Dose Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]-LX4211, Following Oral Administration, in Healthy Male Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 8 (actual)
• Sponsor: Lexicon Pharmaceuticals · Industry
• Sex: Male
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

This phase 1 study is to evaluate the pharmacokinetics (PK), metabolism, routes and extent of elimination of a single oral dose of 400 mg \[14C\]LX4211 to healthy male subjects

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	[14C]-LX4211

Timeline

• Start date: 2013-03-01
• Primary completion: 2013-05-01
• Completion: 2013-05-01
• First posted: 2013-03-26
• Last updated: 2013-06-18

Locations

1 site across 1 country: United States